The actor, who played Uncle Joey on “Full House,” revealed that he was recently diagnosed with HPV-related oropharyngeal ...

On November 28, 2025, Juventas Cell Therapy Co., Ltd. (hereinafter referred to as "Juventas") announced that its independently developed CAR-T cell therapy product, Inaticabtagene Autoleucel (Ina-cel) ...

Circulating tumor DNA (ctDNA) minimal residual disease (MRD) assessment at treatment completion provides superior prognostic accuracy compared with PET in large B-cell lymphoma. The CLARITY assay ...

Axi-cel demonstrated a 90% overall response rate and 75% complete response rate in relapsed/refractory indolent non-Hodgkin lymphoma. Median progression-free survival was 62.2 months, with a median ...

The former 'Full House' star announced his diagnosis during a November 2024 interview. Learn more about Dave's condition.

Dave Coulier is right back in the middle of a scary health battle after beating stage 3 non-Hodgkin Lymphoma earlier this ...

Lunsumio provides high rates of deep and long-lasting responses in third-line and later follicular lymphoma, a disease that typically becomes harder to treat each time a patient relapses1,2Lunsumio ...

The FDA’s Priority Review designation allows for a shortened review period (within 6 months) from the time of application acceptance.

Marks Breyanzi’s fourth indication in Europe, adding to existing approvals for several aggressive B-cell lymphomas.

I thought stress made me sick. It turned out to be cancer — and I had eight kids counting on me to survive. We relied on food ...

In the TRANSCEND MCL trial, 82.7% of patients responded to Breyanzi, with 71.6% of patients achieving complete response Breyanzi demonstrated sustained clinical benefit, with 50.8% of patients still ...